Chemomab Therapeutics to Participate in Cantor Fitzgerald Rare Orphan Disease Summit
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Chemomab Therapeutics Ltd (Nasdaq: CMMB), a clinical-stage biotechnology company, will participate in the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022. Co-founder and Chief Scientific Officer Adi Mor will be a panelist. The discussion will focus on 'Platforms and Pipelines in a Product', highlighting potential applications across various rare diseases. Chemomab specializes in innovative therapies for fibrotic and inflammatory diseases, with their lead product, CM-101, in Phase 2 trials for multiple conditions.
Details
News Market Reaction – CMMB
The recorded move for CMMB in the trading session of this news was -4.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Israel, March 23, 2022 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that management will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 29, 2022.
Adi Mor, PhD, co-founder and Chief Scientific Officer of Chemomab, will participate in the panel.
Cantor Fitzgerald Rare Orphan Disease Summit (virtual)
Panel: Platforms and Pipelines in a Product: How One Concept Could Have Multiple Applications Across Rare Diseases
Presenter: Dr. Adi Mor, Chemomab co-founder and Chief Scientific Officer
Date: March 29, 2022
Time: 9:00 am – 10:15 am ET
Please reach out to your Cantor Fitzgerald representative to access the Rare Orphan Disease Summit.
About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 clinical trials—one in primary sclerosing cholangitis and the second in liver fibrosis, with a Phase 2 trial in systemic sclerosis expected to begin in 2022. For more information on Chemomab, visit www.chemomab.com.
Contacts:
Investor Relations: | Media: |
Irina Koffler | Barbara Lindheim |
LifeSci Advisors, LLC | Chemomab Therapeutics |
Phone: +1-917-734-7387 | Consulting Vice President |
Investor & Public Relations, | |
Strategic Communications | |
Phone: +1-917-355-9234 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/chemomab-therapeutics-to-participate-in-cantor-fitzgerald-rare-orphan-disease-summit-301508580.html
SOURCE Chemomab Therapeutics, Ltd.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.